



Q2 2020

Conference Call

August 5, 2020

This presentation contains forward-looking statements concerning Atomera Incorporated (“Atomera,” the “Company,” “we,” “us,” and “our”). The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those disclosed in the section “Risk Factors” included in our Prospectus Supplement filed pursuant to Rule 424(b)(5) with the SEC on May 13, 2020. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in our forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur.

This presentation contains only basic information concerning Atomera. The Company’s filings with the Securities Exchange Commission, including the Prospectus Supplement, include more information about factors that could affect the Company’s operating and financial results. We assume no obligation to update information contained in this presentation. Although this presentation may remain available on the Company's website or elsewhere, its continued availability does not indicate that we are reaffirming or confirming any of the information contained herein.

*Transistor enhancement
technology for the
\$450B semiconductor market*

*Strong, Growing and
Defensible
Patent Portfolio*




*Top Tier
Management Team*

*High Leverage IP
Licensing Business Model*


**Mears Silicon
Technology (MST®)**
Quantum Engineered Materials

Number of Customer Engagements




- 19 customers, 26 engagements
- Working with 50% of the world's top semiconductor makers*

Customer engagement model




244 Patents Granted and Pending



Core MST Method and Device
MST Enabled Devices/Architecture
Next-Gen Architectures using MST

Discoverable




These distinctive layers are visible on products using MST


Extensive know-how

Extends life and value of patents

300mm Epi tool



300mm Epi Deposition Tool



Source: The McClean Report - 2019

Financial review



	Q2 '19	Q3 '19	Q4 '19	Q1 '20	Q2 '20
GAAP Results					
Revenue	\$0.07M	\$0.25M	\$0.14M	\$0.06M	-
Gross Profit	\$0.05M	\$0.05M	\$0.11M	\$0.05M	-
Operating Expense					
R&D	\$2.1M	\$1.7M	\$1.8M	\$2.1M	\$2.1M
G&A	\$1.5M	\$1.2M	\$1.2M	\$1.4M	\$1.5M
S&M	\$0.2M	\$0.2M	\$0.2M	\$0.2M	\$0.2
Total Operating Expense	\$3.8M	\$3.2M	\$3.2M	(\$3.7M)	(\$3.8M)
Net Loss	(\$3.6M)	(\$3.1M)	(\$3.0M)	(\$3.6M)	(\$3.8M)
<i>Loss Per Share</i>	<i>(\$0.24)</i>	<i>(\$0.19)</i>	<i>(\$0.18)</i>	<i>(\$0.22)</i>	<i>(\$0.21)</i>
Reconciliation between GAAP & Non-GAAP					
Net Loss (GAAP)	(\$3.6M)	(\$3.1M)	(\$3.0M)	(\$3.6M)	(\$3.8M)
Stock-Based Compensation	\$0.8M	\$0.8M	\$0.6M	\$0.6M	\$0.8M
Warrant Modification	-	-	-	\$0.1M	-
Other income (expense)	(\$0.1M)	(\$0.1M)	-	-	-
Adjusted EBITDA (Non-GAAP)*	(\$2.9M)	(\$2.4M)	(\$2.4M)	(\$2.9M)	(\$3.0M)

Balance Sheet 06/30/20	
Cash	\$18.0M
Debt	-
Shares Outstanding	19.8M

*Adjusted EBITDA is a non-GAAP financial measure. A full reconciliation of GAAP and non-GAAP results is contained in our Q2 press release. Some totals reflect rounding.



atomera

Thank You